Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.90 Insider Own0.70% Shs Outstand154.92M Perf Week1.52%
Market Cap5.38B Forward P/E166.27 EPS next Y0.21 Insider Trans-13.24% Shs Float154.92M Perf Month4.10%
Income-139.30M PEG- EPS next Q-0.22 Inst Own98.70% Short Float3.11% Perf Quarter7.12%
Sales1.09B P/S4.92 EPS this Y-0.90% Inst Trans-0.39% Short Ratio5.12 Perf Half Y-14.83%
Book/sh7.53 P/B4.61 EPS next Y-41.78% ROA-7.90% Target Price37.00 Perf Year-24.49%
Cash/sh3.48 P/C9.98 EPS next 5Y41.10% ROE-12.00% 52W Range27.54 - 51.70 Perf YTD17.76%
Dividend- P/FCF180.05 EPS past 5Y-56.50% ROI-7.70% 52W High-32.79% Beta1.80
Dividend %- Quick Ratio2.60 Sales past 5Y20.40% Gross Margin83.90% 52W Low26.18% ATR1.23
Employees2300 Current Ratio2.90 Sales Q/Q14.70% Oper. Margin-9.10% RSI (14)50.29 Volatility3.81% 3.63%
OptionableYes Debt/Eq0.24 EPS Q/Q-182.40% Profit Margin-12.70% Rel Volume0.83 Prev Close34.23
ShortableYes LT Debt/Eq0.24 EarningsApr 25 BMO Payout- Avg Volume940.65K Price34.75
Recom2.90 SMA20-1.02% SMA501.90% SMA200-7.50% Volume781,543 Change1.52%
Dec-19-18Downgrade Goldman Neutral → Sell
Dec-14-18Initiated Wolfe Research Underperform
Dec-13-18Downgrade Credit Suisse Outperform → Underperform
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Apr-25-19 07:00AM  Alkermes Plc Reports First Quarter 2019 Financial Results PR Newswire
06:30AM  Alkermes Plc to Host Earnings Call ACCESSWIRE
Apr-24-19 04:01PM  Alkermes Appoints Industry Veteran C. Todd Nichols as Senior Vice President of Sales and Marketing PR Newswire
01:43PM  Heres What Hedge Funds Think About Alkermes Plc (ALKS) Insider Monkey
Apr-19-19 01:37PM  Has Alkermes plc (NASDAQ:ALKS) Got Enough Cash? Simply Wall St.
Apr-18-19 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2019 Financial Results PR Newswire
10:33AM  Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline Zacks
Apr-11-19 07:48AM  The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug Benzinga
Apr-10-19 10:46AM  Alkermes Reports Positive Data From Schizophrenia Study Zacks
Apr-09-19 07:35AM  Alkermes says long-acting drugs could help schizophrenics stay on medication longer Reuters
07:00AM  Long-acting injectable drugs could help schizophrenics stay on medication longer Reuters
07:00AM  Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA® and INVEGA SUSTENNA® for the Treatment of Schizophrenia PR Newswire
Apr-08-19 05:15PM  Alkermes Announces Departure of Jim Robinson PR Newswire
Apr-07-19 05:04PM  The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts Benzinga
Apr-03-19 07:00AM  Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia PR Newswire
Apr-01-19 12:38PM  Drug companies that benefit from the war on opioid addiction Yahoo Finance
07:00AM  Alkermes to Present New ALKS 3831 Data From ENLIGHTEN-2 and Interim Extension Safety Study Results at 2019 Congress of the Schizophrenia International Research Society PR Newswire
Mar-26-19 11:51AM  Recro Pharma Falls as FDA Denies Approval to Pain Candidate Zacks
Mar-22-19 06:39PM  Top Insider Buys Highlight GuruFocus.com
Mar-21-19 09:54AM  Alkermes Focuses on Pipeline, Depends on Partners for Funds Zacks
Mar-20-19 09:00AM  Industry Consortium Launched to Qualify Biomarkers for Schizophrenia Drug Development Business Wire
Mar-16-19 09:30AM  Why Is Alkermes (ALKS) Up 4.7% Since Last Earnings Report? Zacks
Mar-13-19 03:42PM  Alkermes plcs (NASDAQ:ALKS) Path To Profitability Simply Wall St.
Mar-07-19 08:48AM  Allergan's Depression Candidate Fails in Studies, Stock Down Zacks
Mar-06-19 09:24AM  REVIEWAPALOOZA!: 5-Stock Samplers Motley Fool
Mar-05-19 04:01PM  Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 39th Annual Health Care Conference PR Newswire
Feb-28-19 07:25AM  Research Report Identifies Sunoco LP, Citrix, Alkermes plc, CubeSmart, Morningstar, and Synopsys with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Feb-27-19 04:25PM  Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates Zacks
Feb-26-19 08:32AM  Alkermes' (ALKS) and Biogen's NDA for BIIB098 Accepted by FDA Zacks
07:00AM  Alkermes Initiates Clinical Study of ALKS 4230 Administered Subcutaneously in Patients With Advanced Solid Tumors PR Newswire
Feb-25-19 05:54PM  CLASS ACTION UPDATE for IMMU, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:49PM  FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
02:30PM  CLASS ACTION UPDATE for YRIV, ALKS, MKL and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:48PM  FINAL DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
11:29AM  CLASS ACTION UPDATE for DBVT, ALKS, GSM and MU: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:43AM  DEADLINE ALERT - IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC ACCESSWIRE
07:30AM  Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis GlobeNewswire
Feb-24-19 02:48PM  DEADLINE - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline- February 25, 2019 ACCESSWIRE
02:21PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS ACCESSWIRE
02:00PM  CLASS ACTION UPDATE for DNKEY, ALKS, ATVI and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:40AM  IMMU, ALKS & DXC - Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
10:57AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ALKS, GSM, UXIN and AVP GlobeNewswire
Feb-22-19 05:25PM  CLASS ACTION UPDATE for ALKS, MU, SVXY and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:00PM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
02:07PM  Alkermes Public Limited Company Reminder: Pawar Law Reminds of Important February 25, 2019 Lead Plaintiff Deadline in Class Action ALKS GlobeNewswire
02:01PM  CLASS ACTION UPDATE for DBVT, AXGN, ALKS and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:05PM  Deadline Reminder: The Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Alkermes plc, Inc. (ALKS) GlobeNewswire
12:59PM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
12:47PM  DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
11:13AM  CLASS ACTION UPDATE for IMMU, ALKS, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:00AM  Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) & DXC Technology Company (DXC) - Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
07:30AM  CLASS ACTION UPDATE for PRGO, DBVT, ALKS and W: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-21-19 05:45PM  CLASS ACTION UPDATE for AXGN, ALKS, GE and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
05:16PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline   ALKS GlobeNewswire
04:57PM  Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Alkermes plc (ALKS) GlobeNewswire
03:58PM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline: February 25, 2019 ACCESSWIRE
11:53AM  CLASS ACTION UPDATE for IMMU, DBVT, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:47AM  Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) & DXC Technology Company (DXC) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
09:44AM  The Zacks Analyst Blog Highlights: Intercept, Gilead, Vertex, Alkermes and Clovis Zacks
Feb-20-19 07:45PM  CLASS ACTION UPDATE for ALKS, GSM, ASTE and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
04:30PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alkermes plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
04:11PM  ALKS UPCOMING FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important Deadline in Securities Class Action ALKS GlobeNewswire
04:01PM  Alkermes to Present at the 8th Annual SVB Leerink Global Healthcare Conference PR Newswire
03:45PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline ALKS ACCESSWIRE
02:09PM  CLASS ACTION UPDATE for YOGA, ARLO, ALKS and GSM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:05PM  SINGLE TICKER NOTICE: Pawar Law Group Reminds of February 25 Deadline in Securities Class Action Lawsuit Against Alkermes Public Limited Company ALKS ACCESSWIRE
12:56PM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) and Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
12:17PM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of AXGN, ALKS, MU and TAP GlobeNewswire
10:44AM  Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
10:03AM  Biotech Stock Roundup: ICPT Strong on NASH Drug Data, Collaborations & More Zacks
Feb-19-19 07:00PM  CLASS ACTION UPDATE for ARLO, PRGO, ALKS and ASTE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
03:55PM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
02:50PM  CLASS ACTION UPDATE for GS, ALKS, MU and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:54PM  DEADLINE ALERT -- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
12:41PM  Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
12:37PM  Zhang Investor Law Announces the Filing of a Securities Class Action Lawsuit Against Alkermes Public Limited Company, Alerts of Feb. 25, 2019 Deadline ALKS GlobeNewswire
11:42AM  Edited Transcript of ALKS earnings conference call or presentation 14-Feb-19 1:30pm GMT Thomson Reuters StreetEvents
11:36AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ARLO, ALKS and WRCDF, WCAGY GlobeNewswire
10:33AM  CLASS ACTION UPDATE for IMMU, PRGO, ALKS and VALE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:22AM  Alkermes Breaks $1 Billion Motley Fool
10:00AM  Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) and DXC Technology Company (DXC) and YRC Worldwide Inc. (YRCW): Bronstein, Gewirtz & Grossman, LLC Class Action Update GlobeNewswire
07:00AM  Alkermes and Clovis Oncology Initiate Research Collaboration to Explore Combination Cancer Therapies PR Newswire
Feb-18-19 03:00PM  CLASS ACTION UPDATE for YRIV, ALKS, ASTE and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
10:01AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ARLO, ALKS and WRCDF, WCAGY GlobeNewswire
Feb-17-19 04:03PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alkermes plc. of Class Action Lawsuit and Upcoming Deadline - ALKS ACCESSWIRE
03:00PM  CLASS ACTION UPDATE for ALKS, MKL, MAXR and GSM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:00AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of XRAY, AGN, ALKS and SVXY GlobeNewswire
07:17AM  CLASS ACTION UPDATE for YOGA, IMMU, ALKS and ASTE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-15-19 09:48PM  Alkermes PLC (ALKS) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com
03:20PM  ALKS FEBRUARY 25th DEADLINE: Rosen Law Firm Reminds Alkermes Public Limited Company Investors of Important Deadline in Securities Class Action ALKS GlobeNewswire
02:01PM  CLASS ACTION UPDATE for YRCW, XRAY and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:01PM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
11:00AM  FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GS, ARLO, ALKS and GSM GlobeNewswire
10:40AM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
10:28AM  Alkermes (ALKS) Q4 Earnings & Revenues Surpass Estimates Zacks
09:58AM  JA Solar Holdings Co. Ltd. (JASO), Immunomedics, Inc. (IMMU), Alkermes plc, Inc. (ALKS) Bronstein, Gewirtz & Grossman, LLC Class Action Update ACCESSWIRE
09:44AM  CLASS ACTION UPDATE for ARLO, XRAY, DXC and ALKS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Feb-14-19 06:08PM  Alkermes Plc (ALKS) Q4 2018 Earnings Conference Call Transcript Motley Fool
05:43PM  INVESTOR ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alkermes plc, Inc. (ALKS) & Lead Plaintiff Deadline - February 25, 2019 ACCESSWIRE
04:47PM  CLASS ACTION UPDATE for SOGO, ALKS, W and MKL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; and AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability. It is also developing BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; ALKS 3831 to treat schizophrenia; ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy; and ALKS 5461 for the treatment of depressive disorders. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; license agreement with Acorda Therapeutics, Inc.; and license and collaboration agreement with Biogen Swiss Manufacturing GmbH. It also has a research collaboration with Clovis Oncology, Inc. to evaluate ALKS 4230 in combination with Clovis rucaparib, a PARP inhibitor and lucitanib, an investigational tyrosine kinase inhibitor. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Robinson James A. Jr.President & COO,Alkermes, Inc.Apr 04Option Exercise0.006,25006,250Apr 05 05:10 PM
MITCHELL PAUL JDirectorApr 01Option Exercise8.981,0008,9801,000Apr 02 07:00 PM
MITCHELL PAUL JDirectorApr 01Sale36.641,00036,6400Apr 02 07:00 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Option Exercise8.5525,000213,750210,122Mar 14 06:53 PM
Wysenski NancyDirectorMar 14Buy33.0644514,7124,302Mar 18 05:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 14Sale33.0525,000826,373185,122Mar 14 06:53 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Option Exercise8.5515,829135,338732,262Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 13Sale33.5115,829530,485716,433Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Option Exercise8.5544,171377,662760,604Mar 14 06:38 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 12Sale33.2444,1711,468,447716,433Mar 14 06:38 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Option Exercise8.5520,000171,000205,122Mar 07 06:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 07Sale32.0720,000641,362185,122Mar 07 06:20 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Option Exercise8.5550,000427,500766,433Mar 07 06:16 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 05Sale33.6350,0001,681,740716,433Mar 07 06:16 PM
MITCHELL PAUL JDirectorMar 01Option Exercise8.981,0008,9801,000Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000724,203Mar 04 05:53 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000186,445Mar 04 05:50 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250047,585Mar 04 05:45 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500051,044Mar 04 05:35 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250031,064Mar 04 05:27 PM
MITCHELL PAUL JDirectorMar 01Sale33.481,00033,4800Mar 04 05:13 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000710,590Feb 27 05:20 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250182,717Feb 27 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100045,659Feb 27 05:15 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625047,316Feb 27 05:12 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100029,138Feb 27 05:08 PM
Wysenski NancyDirectorFeb 21Buy33.093,857127,6283,857Mar 18 05:05 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500028,767Feb 19 06:51 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,000045,566Feb 19 06:53 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500703,163Feb 19 07:12 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500045,285Feb 19 06:56 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000180,965Feb 19 07:05 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 16Option Exercise0.003,3750179,074Feb 19 07:05 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOFeb 16Option Exercise0.003,37507,078Feb 19 07:03 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 16Option Exercise0.003,375043,893Feb 19 06:56 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 16Option Exercise0.0018,1250699,753Feb 19 07:12 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 16Option Exercise0.003,375043,664Feb 19 06:53 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 16Option Exercise0.002,375027,092Feb 19 06:51 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise8.981,0008,9801,000Feb 01 05:01 PM
MITCHELL PAUL JDirectorFeb 01Sale32.731,00032,7300Feb 01 05:01 PM
MITCHELL PAUL JDirectorJan 04Option Exercise8.981,0008,9801,000Jan 04 06:01 PM
MITCHELL PAUL JDirectorJan 04Sale30.001,00030,0000Jan 04 06:01 PM
ANSTICE DAVID WDirectorDec 12Option Exercise8.9820,000179,60071,213Dec 13 06:30 PM
ANSTICE DAVID WDirectorDec 12Sale35.598,787312,71066,213Dec 13 06:30 PM
MITCHELL PAUL JDirectorDec 03Option Exercise8.981,0008,9801,000Dec 06 06:10 PM
MITCHELL PAUL JDirectorDec 03Sale36.451,00036,4500Dec 06 06:10 PM
MITCHELL PAUL JDirectorNov 02Option Exercise8.981,0008,9801,000Nov 02 05:22 PM
MITCHELL PAUL JDirectorNov 02Sale37.511,00037,5100Nov 02 05:22 PM
MITCHELL PAUL JDirectorOct 01Option Exercise8.981,0008,9801,000Oct 02 07:52 PM
MITCHELL PAUL JDirectorOct 01Sale42.421,00042,4200Oct 02 07:52 PM
MITCHELL PAUL JDirectorSep 04Option Exercise8.981,0008,9801,000Sep 05 04:22 PM
MITCHELL PAUL JDirectorSep 04Sale44.581,00044,5800Sep 05 04:22 PM
MITCHELL PAUL JDirectorAug 01Option Exercise8.981,0008,9801,000Aug 03 04:26 PM
MITCHELL PAUL JDirectorAug 01Sale43.681,00043,6800Aug 03 04:26 PM
BLOOM FLOYD EDirectorJul 16Sale43.9520,000879,024127,923Jul 18 07:51 PM
MITCHELL PAUL JDirectorJul 03Option Exercise8.981,0008,9801,000Jul 03 05:08 PM
MITCHELL PAUL JDirectorJul 03Sale41.861,00041,8600Jul 03 05:08 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSJun 12Sale50.0016,842842,17937,234Jun 13 08:26 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25001,250Jun 08 05:31 PM
MITCHELL PAUL JDirectorJun 01Option Exercise8.981,0008,9801,000Jun 04 05:18 PM
MITCHELL PAUL JDirectorJun 01Sale47.341,00047,3400Jun 04 05:18 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Option Exercise12.2920,000245,800192,644May 24 05:24 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Sale45.2220,000904,424172,644May 24 05:24 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Option Exercise12.2920,000245,800686,352May 24 05:18 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Sale45.4620,000909,163666,352May 24 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 18Option Exercise12.292753,38036,638May 21 06:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Option Exercise12.2920,000245,800192,644May 17 07:01 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Sale46.1420,000922,846172,644May 17 07:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Option Exercise12.2950,000614,500716,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Sale46.3850,0002,319,100666,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Option Exercise12.2950,000614,500716,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Sale44.3250,0002,215,775666,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Option Exercise12.2950,000614,500716,352May 03 05:13 PM
MITCHELL PAUL JDirectorMay 01Option Exercise8.981,0008,9801,000May 03 05:34 PM
MITCHELL PAUL JDirectorMay 01Sale44.321,00044,3200May 03 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Sale44.0250,0002,201,167666,352May 03 05:13 PM